検索のヘルプ

Location:ホームHot Newsトレーニング/セミナー/シンポジウム情報

IN Cell User's Day 2009 講演要旨

Assay Development Considerations for High Content Screening; Hepatotoxicity and other key Drug Discovery Assays

Andrew Ball Ph.D, HCS Group Leader

Using a GE IN Cell Analyzer 1000 platform as a primary development tool, we have developed a large number of extensively validated High Content Screening assays for multiple stages in the drug discovery and development, from primary screening thru in vitro toxicity assessment. The quality of HCS data is directly related to the quality of the detection reagents employed. Antibodies for HCS carry special requirements. These include strong antigen affinity, minimal non-specific binding, minimized interactions between primary or secondary antibodies, and a sufficient signal:background ratio to ensure an adequate screening window. Additionally, to enable scale up of HCS assays, the assay protocol must be highly reproducible, and the reagents must exhibit minimal assay-to-assay variability. To date, we have successfully developed assays targeting hepatotoxicity, neurotoxicity, cell cycle control, cell signaling, and many cellular stress pathways. We will present data showing that it is possible to use HCS to characterize multiple cellular events in intact cells. For example, Millipore's Hepatotoxicity HCS assay comprises detection reagents and protocols for profiling up to eleven endpoints within a single assay - Cell Loss, Cell Cycle Arrest, DNA Degradation/Apoptosis, Nuclear Size, Oxidative Stress, Stress Kinase Activation, DNA Damage, Mitochondrial Membrane Potential, Mitochondrial Mass, Mitotic Arrest and Cytoskeletal Integrity. Our data demonstrate the assay’s effectiveness in the detection of cellular responses to toxins. The combination of unique antibody pairs and detection reagents allows comprehensive assessment and analysis of the cellular systemic response to toxin challenge. Another example includes data from our Neurotoxicity assays which demonstrate that by multiplexing measurements of neuronal morphology with cell count, HCS represents a more sensitive tool for analysis of neurotoxicity than traditional, widely used cytotoxicity assays. We will also present data showing the utility of our HCS assays for screening key drug targets like p38 MAPK, ERK and many others. In addition to serving as a screening tool, HCS has enabled high levels of quality control for each assay we have developed. Examples of this include extensive characterization of antibody performance, detection of lot-to-lot variation of reagents, assay validation in multiple cell types, and reagent stability. This type of validation data is critical to minimize inter- and intra- assay variation. In conclusion, Millipore has developed a large portfolio of highly-validated HCS assays representing comprehensive workflow solutions for drug screening, and for in vitro toxicology assessment - representing broad potential for drug discovery and development.

Millipore Corporation
Bioscience Division
28820 Single Oak Drive
Temecula
CA 92590
USA


お問合せフォーム
※よくあるお問合せとご回答(FAQ)は「こちらで»」ご覧いただけます。
※ファイルを添付してのお問合せは、お手数ですが「Tech-JP@ge.comまでメールにて」お問合せください。
お問合せ内容[必須] お名前[必須]  

注)機種依存文字(①、② など)は使用できません。
大学/企業名[必須]
E-mail[必須]
電話[必須] - - (内線
ご記入いただく個人情報は、当社製品・サービスの提供及び販売促進、当社製品に関する情報の収集・分析及 び提供、新製品・新サービスの研究開発等並びに市場調査のために利用します。当社は個人情報を業務委託 先に預ける場合がありますが、個人情報の取扱いに関する法令、国が定める指針その他の規範に従い、委託先 に対する必要かつ適切な監督を行います。個人情報に関するお問い合わせは個人情報相談窓口(042-5855111:平日午前10時~午後5時)にて承ります。 GEヘルスケア・ジャパン株式会社 個人情報管理責任者
個人情報保護に対する基本方針